Colin O’Dowd
Colin O’Dowd
Colin O’Dowd
Colin manages the medicinal chemistry, ADMET and CADD groups within Almac Discovery bringing to bear his experience in chemistry contract research from his 9 year tenure in Almac Sciences.
Click to Read MoreColin has broad medicinal chemistry skills, he and his team have recently worked on Discovery’s kinase and deubiquitylating enzyme programmes and platform. He was heavily involved in implementing and delivering the initial phases of the highly successful industry-academia research collaboration between Almac Discovery and Queen’s University Belfast which continues with the Centre for Precision Therapeutics in 2016.
He has a Ph.D in synthetic organic chemistry from Queen’s University.